Robert Milne is a member of White & Case’s internationally recognised global antitrust group and focuses on complex antitrust litigation (civil and criminal) and counselling matters. He is widely regarded as a leading practitioner in these areas based on his significant experience and track record, winning notable victories in cases where billions of dollars were at stake. Mr Milne was recently named to Law360’s “MVP” list of top antitrust lawyers in the country, and was separately named as a top life sciences lawyer by the same publication. He has also been recognised as a “Forty Under Forty” top litigator by the National Law Journal and as a leading antitrust practitioner by such publications as Chambers USA, The Legal 500: United States, Best Lawyers in America and Benchmark Litigation.
Mr Milne has litigated cases throughout the United States, including matters before the US Federal Trade Commission and other government agencies. He has a particularly deep knowledge and experience in the pharmaceutical, construction, energy and financial services industries, and much of his work involves clients based outside the United States and/or matters having significant international dimensions.
Prior to entering private practice, Mr Milne served as a trial attorney for the antitrust division of the US Department of Justice, where he worked on civil and criminal matters around the United States.
Recent work includes representing a range of leading pharmaceutical companies in nationwide class action lawsuits claiming that the pharmaceutical firms delayed entry of generic competition through allegedly unlawful procurement or enforcement of patents and/or settlement of patent litigation. Among Mr Milne’s clients in these cases are Pfizer, Wyeth, Boehringer Ingelheim and Warner Chilcott (now Allergan). Mr Milne secured important dismissals of such claims in three of these litigations, on behalf of Pfizer (relating to Lipitor, the largest-selling pharmaceutical of all time), Wyeth (relating to Effexor XR, a blockbuster antidepressant) and Warner Chilcott (relating to Loestrin, a well-known oral contraceptive). Mr Milne also handled the first jury trial of an antitrust challenge to a claimed “reverse payment” patent settlement, securing a verdict in favour of his client Geneva Pharmaceuticals.
Additional recent work includes: representing the Organization of the Petroleum Exporting Countries (OPEC) against claims of price fixing of petroleum-based products, recently securing dismissal of such claims; CertainTeed Gypsum, a leading construction products company, in nationwide class actions alleging price-fixing in the sale of gypsum wallboard; Saudi Aramco, the national oil company of the Kingdom of Saudi Arabia, securing dismissal of nationwide class actions challenging the activities of OPEC members; the Belarusian Potash Company, one of the world’s leading suppliers of potash, against class actions alleging a global cartel; Experian Information Solutions, securing dismissal of class action litigation alleging a conspiracy among major financial institutions, credit reporting agencies and credit scoring companies to fix consumer interest rates; and Novartis Pharmaceuticals Corporation, securing voluntary dismissal of class action challenges to co-payment assistance programmes for brand-name pharmaceuticals. He also secured a jury verdict in favour of Experian Information Solutions in an action alleging that the three major US credit bureaux committed trademark infringement and unfair competition in the sale of credit scoring services.